GRI BIO INC (GRI)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.88+25.76%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · GRI
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -55.9% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
GRI — earnings miss
Dated 2026-02-04
Results of Operations and Financial Condition. On February 4, 2026, GRI Bio, Inc. (the “Company”) issued a press release reiterating its financial results for the fiscal year 2025 and summarizing key recent highlights. A copy of the Company’s press release containing this information is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Se…
Why it matters: Advancing GRI-0803 could expand GRI Bio's pipeline and address autoimmune diseases. This may enhance long-term growth prospects.
Supportive ifThey announced that studies for GRI-0803 are now complete.
Worry ifDelays or problems in the IND activities for GRI-0803.
Why it matters: Updates on cash reserves will show if GRI Bio can fund operations until 2027.
Worry ifCash and cash equivalents are over $11 million. This confirms funding until Q2 2027.
Less concerning ifCash and cash equivalents fall below $8 million. This raises worries about funding operations.
Why it matters: New data may show GRI-0621 can help treat idiopathic pulmonary fibrosis. Good results might get more investors interested.
Supportive ifManagement shares more positive results from the Phase 2a trials for GRI-0621.
Worry ifNew data shows GRI-0621 does not make treatments safer or more effective.
Why it matters: Updates could show progress in getting GRI-0621 approved. This helps keep market exclusivity.
Supportive ifFDA supports GRI-0621's Orphan Drug Designation. This could lead to market exclusivity.
Worry ifFDA delays or questions the Orphan Drug Designation for GRI-0621.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$314 on $10,000 · ±3.1% | How much price usually moves either way. |
| Bad day | $1,275 loss on $10,000 · 12.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,782 loss on $10,000 · 97.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Good data would show GRI-0621 can help treat idiopathic pulmonary fibrosis. This could help investors.
Supportive ifPhase 2a data shows big gains in lung function. It also shows better tolerability than placebo.
Worry ifData shows no big improvements or safety issues that hurt the drug's profile.
Why it matters: Good feedback can help move to important studies. This can increase the drug's value.
Supportive ifFDA gives guidance to help GRI-0621 move to important studies.
Worry ifFDA raises concerns that delay the regulatory pathway for GRI-0621.
Why it matters: Positive data would support GRI-0621's potential as a new treatment for IPF. It could strengthen investor confidence in the pipeline.
Supportive ifNew results from the Phase 2a trial show better cough and diarrhea than placebo.
Worry ifPhase 2a data show no clear change in cough or diarrhea compared to placebo.